Mitchell Halper
Psychiatry · St Charles, ILNPI 1205039658
Payments from drug & device makers
Across 145 payments — averaging $81.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$9K
- Lundbeck LLC$697
- Teva Pharmaceuticals USA, Inc.$421
- Neurocrine Biosciences, Inc.$287
- Corium, LLC$223
- Axsome Therapeutics, Inc.$221
- plus $636 from 11 others
What the payments were for
- Speaking & faculty fees$8,77574%
- Travel & lodging$911%
- Food & beverage$2,88924%
- Education$861%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 44 | $9,356 |
| Lundbeck LLC | 26 | $697 |
| Teva Pharmaceuticals USA, Inc. | 15 | $421 |
| Neurocrine Biosciences, Inc. | 9 | $287 |
| Corium, LLC | 10 | $223 |
| Axsome Therapeutics, Inc. | 9 | $221 |
| Johnson & Johnson | 10 | $213 |
| Otsuka America Pharmaceutical, Inc. | 4 | $93 |
| Alkermes, Inc. | 4 | $75 |
| Supernus Pharmaceuticals, Inc. | 3 | $60 |
| Ironshore Pharmaceuticals Inc. | 4 | $55 |
| Collegium Pharmaceutical, Inc. | 1 | $35 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $35 |
| E.r. Squibb & Sons, L.L.C. | 1 | $22 |
| Sunovion Pharmaceuticals Inc. | 1 | $18 |
| Indivior Inc. | 1 | $17 |
| Shire North American Group Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$8,775
How this compares
$11,840 in reported general payments places this provider in the 90th percentile of 1,344 psychiatry providers in Illinois.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 22 | $33,020 |
| RexultiBrexpiprazole | 12 | $17,496 |
| TrintellixVortioxetine Hydrobromide | 26 | $12,916 |
| Aripiprazole | 26 | $3,817 |
| Quetiapine Fumarate | 92 | $1,501 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 45 | $1,217 |
| Alprazolam | 81 | $1,039 |
| Bupropion XlBupropion Hcl | 23 | $430 |
| Duloxetine Hcl | 32 | $389 |
| Olanzapine | 23 | $376 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 14 | $353 |
| Mirtazapine | 32 | $299 |
| Naltrexone Hcl | 12 | $258 |
| Lamotrigine | 22 | $204 |
| Escitalopram Oxalate | 22 | $190 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $9,356 | $33,02022 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $93 | $17,49612 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,344 psychiatry providers in Illinois.
Other psychiatry in St Charles
- Jeffrey RossNorthbrook$10.8M
- Yuhwen ChowChicago$8.5M
- Mark LermanNorthbrook$4.5M
- Danesh AlamWinfield$2.7M
- John ZajeckaSkokie$2.5M
- Riaz BaberNaperville$2.4M
- Michael GreenbaumLibertyville$2.2M
- Sandeep GaonkarNaperville$1.8M
- Jon GrantChicago$1.4M
- David KempOak Lawn$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.